神经母细胞瘤与 MYCN
Neuroblastoma and MYCN.
机构信息
Departments of Neurology, Pediatrics, and Neurosurgery, University of California, San Francisco, California 94158-9001.
出版信息
Cold Spring Harb Perspect Med. 2013 Oct 1;3(10):a014415. doi: 10.1101/cshperspect.a014415.
Abstract
Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to originate from undifferentiated neural crest cells. Amplification of the MYC family member, MYCN, is found in ∼25% of cases and correlates with high-risk disease and poor prognosis. Currently, amplification of MYCN remains the best-characterized genetic marker of risk in neuroblastoma. This article reviews roles for MYCN in neuroblastoma and highlights recent identification of other driver mutations. Strategies to target MYCN at the level of protein stability and transcription are also reviewed.
摘要
神经母细胞瘤是儿童最常见的颅外实体瘤，被认为起源于未分化的神经嵴细胞。在约 25%的病例中发现 MYC 家族成员 MYCN 扩增，与高危疾病和预后不良相关。目前，MYCN 扩增仍然是神经母细胞瘤风险的最佳特征性遗传标志物。本文综述了 MYCN 在神经母细胞瘤中的作用，并强调了最近对其他驱动突变的鉴定。还综述了靶向 MYCN 蛋白稳定性和转录水平的策略。
相似文献
1
Neuroblastoma and MYCN.神经母细胞瘤与 MYCN
Cold Spring Harb Perspect Med. 2013 Oct 1;3(10):a014415. doi: 10.1101/cshperspect.a014415.
2
The MYCN oncogene and differentiation in neuroblastoma.MYCN 癌基因与神经母细胞瘤分化。
Semin Cancer Biol. 2011 Oct;21(4):256-66. doi: 10.1016/j.semcancer.2011.08.001. Epub 2011 Aug 9.
3
Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.功能型 MYCN 特征可预测神经母细胞瘤的预后，而与 MYCN 扩增无关。
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19190-5. doi: 10.1073/pnas.1208215109. Epub 2012 Oct 22.
4
Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.逆转录病毒介导的抗MYCN短发夹RNA的条件性表达作为一种体外模型系统，用于研究MYCN扩增的神经母细胞瘤中的神经元分化。
BMC Dev Biol. 2011 Jan 3;11:1. doi: 10.1186/1471-213X-11-1.
5
In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.神经母细胞瘤的体内血管生成活性与MYCN癌基因的过表达相关。
Int J Cancer. 2002 Dec 1;102(4):351-4. doi: 10.1002/ijc.10742.
6
ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.ID2的表达与人类神经母细胞瘤中的MYCN扩增或表达无关。
Cancer Res. 2003 Apr 1;63(7):1631-5.
7
Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma.循环中的MYCN DNA可预测神经母细胞瘤中的MYCN扩增。
J Clin Oncol. 2005 Dec 1;23(34):8919-20; author reply 8920. doi: 10.1200/JCO.2005.04.0170.
8
MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.MYCN 和 MYC 通过 BMI1 直接调节人神经母细胞瘤的肿瘤增殖和肿瘤发生。
FASEB J. 2011 Dec;25(12):4138-49. doi: 10.1096/fj.11-185033. Epub 2011 Aug 19.
9
Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma.多种机制破坏神经母细胞瘤中的let-7微小RNA家族。
Nature. 2016 Jul 14;535(7611):246-51. doi: 10.1038/nature18632. Epub 2016 Jul 6.
10
Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology.人类神经母细胞瘤中MYCN基因扩增：分子遗传学向临床肿瘤学转化的范例
Ann N Y Acad Sci. 2002 Jun;963:63-73.
引用本文的文献
1
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity.RBM39降解剂可增强先天免疫以根除神经母细胞瘤，尽管癌细胞具有可塑性。
Nat Commun. 2025 Sep 17;16(1):8287. doi: 10.1038/s41467-025-63979-x.
2
Mycn Is Essential for Pubertal Mammary Gland Development and Promotes the Activation of Bcl11b-Maintained Quiescent Stem Cells.Mycn对青春期乳腺发育至关重要，并促进由Bcl11b维持的静止干细胞的激活。
Cells. 2025 Aug 12;14(16):1239. doi: 10.3390/cells14161239.
3
Novel endoplasmic reticulum stress-related gene signature unveils CDKN3 as a prognosticator in neuroblastoma.新型内质网应激相关基因特征揭示CDKN3作为神经母细胞瘤的预后指标。
Transl Pediatr. 2025 Jul 31;14(7):1471-1488. doi: 10.21037/tp-2025-142. Epub 2025 Jul 28.
4
TNFSF14-HVEM/LTβR Exacerbates Keratinocyte Abnormalities and IMQ-Induced Psoriatic Skin Inflammation via Activating NF-κB/TWIST1 Signalling Pathway.TNFSF14-HVEM/LTβR通过激活NF-κB/TWIST1信号通路加剧角质形成细胞异常和咪喹莫特诱导的银屑病皮肤炎症。
J Cell Mol Med. 2025 Aug;29(15):e70774. doi: 10.1111/jcmm.70774.
5
Identification of Prognostic Biomarkers in Gene Expression Profile of Neuroblastoma Via Machine Learning.通过机器学习鉴定神经母细胞瘤基因表达谱中的预后生物标志物
Pediatr Discov. 2025 May 27;3(2):e70009. doi: 10.1002/pdi3.70009. eCollection 2025 Jun.
6
Diagnostic technologies for neuroblastoma.神经母细胞瘤的诊断技术
Lab Chip. 2025 Jul 14. doi: 10.1039/d4lc00005f.
7
High-risk neuroblastoma in Mexico: from multimodal treatment to immunotherapy. Regarding the first case treated with naxitamab.墨西哥的高危神经母细胞瘤：从多模式治疗到免疫疗法。关于首例接受纳昔妥单抗治疗的病例。
Front Oncol. 2025 Jun 18;15:1520171. doi: 10.3389/fonc.2025.1520171. eCollection 2025.
8
Pharmacologic inhibition of BMI1 exerts antitumor effects against MYCN-amplified neuroblastoma, with activation of the p53 pathway.BMI1的药理学抑制作用通过激活p53途径，对MYCN扩增的神经母细胞瘤发挥抗肿瘤作用。
Sci Rep. 2025 Jul 2;15(1):22917. doi: 10.1038/s41598-025-06922-w.
9
Peripheral neuroblastic tumors: tumor biology and its implications for risk stratification.外周神经母细胞瘤：肿瘤生物学及其对风险分层的意义
Eur J Pediatr. 2025 Jun 25;184(7):447. doi: 10.1007/s00431-025-06281-8.
10
Disruption of the KLHL37-N-Myc complex restores N-Myc degradation and arrests neuroblastoma growth in mouse models.KLHL37-N-Myc复合物的破坏可恢复N-Myc的降解，并在小鼠模型中抑制神经母细胞瘤的生长。
J Clin Invest. 2025 Jun 10;135(14). doi: 10.1172/JCI176655. eCollection 2025 Jul 15.
本文引用的文献
1
MYC degradation.MYC 降解。
Cold Spring Harb Perspect Med. 2014 Mar 1;4(3):a014365. doi: 10.1101/cshperspect.a014365.
2
Genome recognition by MYC.MYC对基因组的识别
Cold Spring Harb Perspect Med. 2014 Feb 1;4(2):a014191. doi: 10.1101/cshperspect.a014191.
3
Roles for MYC in the establishment and maintenance of pluripotency.MYC 在多能性的建立和维持中的作用。
Cold Spring Harb Perspect Med. 2013 Dec 1;3(12):a014381. doi: 10.1101/cshperspect.a014381.
4
The role of MIZ-1 in MYC-dependent tumorigenesis.MIZ-1 在 MYC 依赖性肿瘤发生中的作用。
Cold Spring Harb Perspect Med. 2013 Dec 1;3(12):a014290. doi: 10.1101/cshperspect.a014290.
5
Role of MYC in Medulloblastoma.MYC 在髓母细胞瘤中的作用。
Cold Spring Harb Perspect Med. 2013 Nov 1;3(11):a014308. doi: 10.1101/cshperspect.a014308.
6
Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.组蛋白H3.3突变通过上调MYCN驱动小儿胶质母细胞瘤。
Cancer Discov. 2013 May;3(5):512-9. doi: 10.1158/2159-8290.CD-12-0426.
7
Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.Th-MYCN 小鼠伴有半胱天冬酶-8 缺陷会发展为伴有骨髓转移的晚期神经母细胞瘤。
Cancer Res. 2013 Jul 1;73(13):4086-97. doi: 10.1158/0008-5472.CAN-12-2681. Epub 2013 Mar 27.
8
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.TERT 启动子突变在神经胶质瘤和一小部分源自自我更新率低的细胞的肿瘤中频繁发生。
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6. doi: 10.1073/pnas.1303607110. Epub 2013 Mar 25.
9
CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.CDK4 抑制在多柔比星诱导的 DNA 损伤情况下恢复 MYCN 扩增神经母细胞瘤细胞的 G1-S 期阻滞。
Cell Cycle. 2013 Apr 1;12(7):1091-104. doi: 10.4161/cc.24091. Epub 2013 Mar 5.
10
Constitutively active TrkB confers an aggressive transformed phenotype to a neural crest-derived cell line.组成型激活的 TrkB 赋予神经嵴来源的细胞系侵袭性转化表型。
Oncogene. 2014 Feb 20;33(8):977-85. doi: 10.1038/onc.2013.39. Epub 2013 Mar 4.
Zotero 插件